South Korean regenerative medicine company ROKIT Healthcare has signed a strategic agreement with UAE-based investment firm Master Investment Group (MIG) to establish a joint venture in the Middle East, marking a major step toward expanding AI-driven organ regeneration technologies in the region.
The partnership includes an investment of approximately $20–20.7 million from MIG and will lead to the creation of a new entity tentatively named ROKIT MENA, which will focus on deploying regenerative medicine platforms, advanced diagnostics, and AI-driven healthcare services across the Gulf region.
The venture aims to position the UAE as a hub for next-generation biotechnology and personalized medicine.
What the ROKIT–MIG joint venture will focus on
The new joint venture will combine ROKIT Healthcare’s proprietary AI-powered organ regeneration technologies with the financial and strategic backing of Master Investment Group.
Under the agreement:
- Master Investment Group will provide approximately $20 million in investment capital.
- ROKIT Healthcare will contribute its proprietary regenerative medicine technologies and AI platforms as part of the venture.
The partnership plans to build regenerative medicine clinics and localized manufacturing facilities in the UAE. These centers will support the development and distribution of therapies that regenerate damaged tissues and organs using patient-specific biological data.
The initiative is expected to accelerate the adoption of advanced medical technologies in the Middle East while creating a new ecosystem for biotech innovation.
ROKIT Healthcare’s AI-based regenerative medicine platform
Founded in South Korea, ROKIT Healthcare is known for its work in AI-driven organ regeneration and 3D bioprinting technologies.
The company develops treatments designed to repair or regenerate damaged tissues such as:
- Skin
- Cartilage
- Kidneys
- Other organs affected by chronic disease or injury
Its platform integrates artificial intelligence, precision diagnostics, and 3D bioprinting to create personalized therapies tailored to each patient’s biological profile.
The technology is also being explored for applications in anti-aging medicine and personalized regenerative therapies, sectors that are rapidly growing worldwide.
UAE royal-linked investment signals strategic push into biotech
The deal is backed by Sheikh Abdullah bin Mohammed bin Saqr Al Qasimi, the CEO of Master Investment Group.
According to the companies, Sheikh Abdullah recently visited ROKIT Healthcare’s headquarters in Seoul to review the firm’s technology and discuss long-term collaboration plans.
The involvement of a UAE royal-linked investment group signals the country’s increasing interest in advanced healthcare technologies and biotechnology innovation.
The UAE has been actively investing in sectors such as AI, healthtech, and life sciences as part of its broader strategy to diversify the economy beyond oil.
UAE to serve as the regional base for expansion
The newly formed ROKIT MENA will use the UAE as its operational base for expansion across the broader Middle East and beyond.
Initial expansion plans include:
- The United Arab Emirates
- Saudi Arabia
- Other Gulf Cooperation Council (GCC) markets
The companies estimate that the potential market could include more than 15 million patients across the region, particularly those suffering from chronic diseases, tissue damage, and degenerative conditions.
Beyond the Middle East, the partnership also intends to explore opportunities in Europe and other global markets.
Building a regional hub for regenerative medicine
As part of the joint venture, the partners plan to establish:
- Regenerative medicine treatment centers
- Local manufacturing capabilities for medical products
- AI-based diagnostic and therapy platforms
These facilities could help reduce dependence on imported medical treatments while strengthening the UAE’s ambition to become a global destination for advanced healthcare and medical tourism.
The integration of AI with regenerative medicine could also enable more scalable and personalized treatment models in the region.
What this deal means for UAE startups and the regional ecosystem
This partnership goes beyond a single joint venture—it signals a broader shift in how the UAE is positioning itself in the global startup and innovation landscape.
1. Stronger push into deep-tech startups
The deal shows that UAE investors are moving beyond fintech and e-commerce into deep-tech sectors like biotech, AI, and healthcare, which require longer-term capital and infrastructure.
2. More global startup collaborations
By partnering with a South Korean company, the UAE is opening doors for cross-border startup partnerships, especially between Asia and the Middle East. This could attract more international startups to set up regional bases in the UAE.
3. Opportunity for local healthtech founders
Local startups in healthtech, diagnostics, AI, and medtech may benefit from:
- Better infrastructure
- Access to advanced technology
- Potential partnerships with global players
4. Rise of the UAE as a biotech hub
With investments like this, the UAE is steadily building its position as a biotech and medical innovation hub, similar to how it built strength in fintech and logistics.
5. Growth to medical tourism and startup demand
Advanced treatments like organ regeneration and anti-aging solutions can attract high-value medical tourism, creating demand for startups in:
- Digital health platforms
- Patient experience
- Healthcare logistics
The bottom line
The ROKIT Healthcare–MIG joint venture highlights a growing alignment between global biotech innovation and Middle Eastern capital.
For startups, especially in the UAE, it opens new opportunities in deep tech, healthcare, and cross-border innovation.
